BioCryst Pharmaceuticals, Inc. (BCRX): Price and Financial Metrics


BioCryst Pharmaceuticals, Inc. (BCRX)

Today's Latest Price: $5.43 USD

0.09 (-1.63%)

Updated Jul 10 4:00pm

Add BCRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

BCRX Stock Summary

  • Biocryst Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 97.43% of US listed stocks.
  • BCRX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 0.59% of US stocks.
  • As for revenue growth, note that BCRX's revenue has grown 111.71% over the past 12 months; that beats the revenue growth of 94.96% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Biocryst Pharmaceuticals Inc, a group of peers worth examining would be LXRX, STX, HALO, STRO, and TNAV.
  • Visit BCRX's SEC page to see the company's official filings. To visit the company's web site, go to www.biocryst.com.
BCRX Daily Price Range
BCRX 52-Week Price Range

BCRX Stock Price Chart Technical Analysis Charts


BCRX Price/Volume Stats

Current price $5.43 52-week high $6.29
Prev. close $5.53 52-week low $1.38
Day low $5.24 Volume 5,610,965
Day high $5.60 Avg. volume 8,304,291
50-day MA $4.66 Dividend yield N/A
200-day MA $3.16 Market Cap 957.86M

BioCryst Pharmaceuticals, Inc. (BCRX) Company Bio


Biocryst Pharmaceuticals designs, optimizes and develops novel small molecule drugs that block key enzymes involved in rare diseases. The company was founded in 1986 and is based in Durham, North Carolina.


BCRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

BCRX Latest Social Stream


Loading social stream, please wait...

View Full BCRX Social Stream

Latest BCRX News From Around the Web

Below are the latest news stories about Biocryst Pharmaceuticals Inc that investors may wish to consider to help them evaluate BCRX as an investment opportunity.

BioCryst Pharmaceuticals Jumped Higher Today; Here's Why Investors May Be Wrong

There might be a simple explanation for why the company doubled the expected enrollment in its COVID-19 clinical trial.

Yahoo | July 7, 2020

What You Need To Know About BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Investor Composition

If you want to know who really controls BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), then you'll have to look at the...

Yahoo | July 7, 2020

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

Is (BCRX) Outperforming Other Medical Stocks This Year?

Yahoo | July 7, 2020

Gilead's Remdesivir Sold Out Already

Gilead Sciences (GILD) recently announced pricing for remdesivir, the company's COVID-19 drug, finally delivering some certainty to the market. Questions remained over how soon GILD would be bringing in revenues based on the fact that GILD has been donating vials of remdesivir up to this point. Who bought all the...

Biotech Beast on Seeking Alpha | July 2, 2020

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted five newly-hired employees inducement options to purchase an aggregate of 70,000 shares of BioCryst common stock on June 30, 2020 as inducements material to each employee entering into employment with BioCryst. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $4.77 per share, which is equal to the closing price of BioCryst common stock on the last business day prior to the grant date.

Yahoo | July 2, 2020

Read More 'BCRX' Stories Here

BCRX Price Returns

1-mo 26.57%
3-mo 131.06%
6-mo 96.38%
1-year 50.83%
3-year -7.02%
5-year -66.87%
YTD 57.39%
2019 -57.25%
2018 64.36%
2017 -22.43%
2016 -38.66%
2015 -15.13%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9082 seconds.